Particle Engineering Company Enavail Announces New cGMP Pharmaceutical Manufacturing Facility to Be Located in the Abilene Life Sciences Accelerator

The Enavail cGMP Facility Will Be the First in the West Texas Region

ABILENE, Texas & AUSTIN, Texas--(BUSINESS WIRE)--Jun 9, 2010 - Enavail, LLC, a particle engineering company founded on pioneering drug delivery research from the University of Texas at Austin, announced today the company's plans for the construction of a new state-of-the-art current Good Manufacturing Practices (cGMP) facility in the Abilene Life Sciences Accelerator (ALSA). The Enavail facility will be the first of its kind in the West Texas region.

Enavail is an Emergent Technologies, Inc. (ETI) portfolio company, headed by Brian Windsor, Ph.D., President and Breca Tracy, Ph.D., Assistant Managing Director. Enavail's scientific team is led by Chief Scientist Robert O. (Bill) Williams III, Ph.D., Professor of Pharmaceutics in The University of Texas at Austin College of Pharmacy. Enavail's particle engineering technologies allow for tremendous enhancement of drugs with poor water solubility – a condition that can greatly limit a drug's effectiveness.

“The strategic decision to build our new cGMP facility in Abilene was based on a thorough review of our options,” said Enavail President Brian Windsor. “The space and the services the Abilene Life Sciences Accelerator have to offer are a perfect fit for us. They will allow for ongoing support for our clients' clinical and commercial GMP needs. We presently offer phase I cGMP clinical batch production for compounds with applications in pulmonary, parenteral, intranasal and oral delivery. The Abilene facility will allow us to support all clinical phases as well as commercial manufacturing.”

“Having the GMP facility in the ALSA will better help us to fast-track the growth of our client companies, Abilene and West Texas,” David Sougstad, ALSA Executive Director commented. “It represents a substantial new life sciences manufacturing asset in the region.”

Richard Burdine, CEO, Development Corporation of Abilene, said, “Enavail's cGMP facility is another first for Abilene in the life sciences industry and a first for the whole West Texas region. It is in keeping with our goal to bring innovative technology to the City of Abilene and this area. It furthers our efforts to provide valuable job and innovation led economic development opportunities for Abilene.”

Utilizing its state-of-the-art lab in Austin and the planned cGMP facility in Abilene, Enavail works with collaborative partners in drug development that are interested in improved formulations, product development and clinical scale manufacturing. Co-development projects usually begin with feasibility studies for development of custom-tailored solutions for partners directed to their specific active ingredient. These are followed by cGMP clinical batch production and licensing of the Enavail technologies for commercialization of products. In addition to client services, Enavail is in development of its own proprietary pharmaceutical products.

The planned 1,800 sq. ft. facility will be built in compliance with the current Good Manufacturing Practices (cGMP) set forth in the FDA's code of federal regulations, 21 CFR parts 210 and 211; and will support clinical batch production and commercial scale manufacturing. Facility completion is anticipated by September of this year.

About Enavail

Enavail is a particle engineering pharmaceutical company founded on the pioneering research of Dr. Robert O. (Bill) Williams III, Dr. Keith Johnston and their teams at The University of Texas at Austin. With state-of-the-art research facilities located in Austin, Texas, Enavail provides particle engineering expertise for pharmaceutical, biotech and nutraceutical companies. Enavail's core technologies are focused on two key areas: a) generating crystalline or amorphous forms of poorly water-soluble compounds, providing high potency and greatly enhanced dissolution and bioavailability, and b) producing high surface area, non-degraded powder forms of labile proteins and peptides. Enavail is managed and funded by Emergent Technologies, Inc., a life sciences investment and management company. For more information, visit www.enavail.com.

About the ETI Innovation Services Group

The ETI Innovation Services Group is a specialty practice group within life sciences technology investment and management company Emergent Technologies, Inc. (ETI). The Innovation Services Group provides clients with technology opportunities in order to achieve both economic development and wealth creation for communities. The practice offers business solutions to companies, organizations and communities of all sizes. For more information, please visit www.etibio.com/ETIInnovationServices.

About the Abilene Life Sciences Accelerator (ALSA)

The Abilene Life Sciences Accelerator (ALSA) is part of a major initiative to diversify the economy of Abilene and the region. The life sciences accelerator offers affordable lease rates for early-stage biotech companies (our clients) as they grow to profitability. Access to leading-edge equipment is included in the base lease as one of many services offered clients in the ALSA. Private sector/University research collaborations are welcomed by faculty at the TTUHSC School of Pharmacy in Abilene and our three local private universities. Coordination with angel investors is offered for clients on-the-grow. Biotech workforce development is ongoing at the high school and college level and we seek input from our clients on course content. Also, outstanding community support provides early-stage biotech companies recognition and appreciation for their contributions to our regional economy. For more information about the ASLA or our services, please visit our website www.abileneaccelerator.com or call 325-672-1883.

About Emergent Technologies, Inc.

Emergent Technologies, Inc. (ETI) is a life sciences and technology investment and management company which provides early stage funding and development for scientific discoveries originating at universities and research institutions. The Company creates value by transforming scientific breakthroughs into technology platforms with multiple applications. ETI's unique innovation process enables the Company to select promising scientific discoveries for development, maximize the value of intellectual property and manage both cost and risk associated with the commercial development of early stage technologies. ETI is dedicated to turning research into revenue and, in the process, introducing compelling solutions to meet important market needs. For more information, visit the company website www.etibio.com.

 

Contact: Nsight Public Relations
Sandra Oak, 321-591-1508
soak@nsightpr.com

 

Posted: June 2010

View comments

Hide
(web2)